Table 5.
Selected gene-vitamin B interactions and risk of colorectal adenomas
| No. recurrences /total | ||||
|---|---|---|---|---|
| Genotype | Vitamin B level below the median (reference) | Vitamin B level above the median | Adjusted RR (95% CI)* | P for interaction |
| Baseline plasma vitamin B2 (riboflavin) | 2.1-15.0 nmol/L | 15.1-479.0 nmol/L | ||
| MTHFR-677 CC+C/T | 195/413 | 179/416 | 0.87 (0.73-1.03) | |
| MTHFR-677 T/T | 18/52 | 19/44 | 1.40 (0.85-2.30) | 0.07 |
| MTHFR-1298 A/A+A/C | 197/431 | 178/416 | 0.90 (0.76-1.07) | |
| MTHFR-1298 C/C | 16/35 | 21/45 | 0.92 (0.56-1.54) | 0.94 |
| Baseline plasma vitamin B6 (PLP) | 21.4-300.3 pmol/L | 300.5-2479 pmol/L | ||
| CBS-1080 C/C+C/T | 182/403 | 159/402 | 0.90 (0.75-1.08) | |
| CBS-1080 T/T | 37/56 | 32/62 | 0.72 (0.49-1.03) | 0.25 |
| CBS-699 C/C+C/T | 195/404 | 179/422 | 0.89 (0.75-1.06) | |
| CBS-699 T/T | 25/57 | 13/44 | 0.67 (0.40-1.13) | 0.30 |
| MTHFR-677 CC+C/T | 196/410 | 178/419 | 0.90 (0.76-1.07) | |
| MTHFR-677 T/T | 24/51 | 13/45 | 0.66 (0.39-1.10) | 0.25 |
| Baseline plasma vitamin B12 | 4.7-53.3 nmol/L | 53.4-857.0 nmol/L | ||
| MTR 2756-A/A | 72/155 | 63/151 | 0.92 (0.71-1.20) | |
| MTR 2756- A/G + G/G | 151/310 | 127/314 | 0.87 (0.72-1.05) | 0.70 |
| MTRR 66-A/A+A/G | 163/335 | 139/342 | 0.86 (0.72-1.03) | |
| MTRR 66-G/G | 59/129 | 51/123 | 0.96 (0.72-1.29) | 0.50 |
| MTHFR-677 CC+C/T | 198/411 | 177/421 | 0.90 (0.77-1.07) | |
| MTHFR-677 T/T | 24/52 | 13/45 | 0.69 (0.41-1.17) | 0.33 |
*
Adjusted for age, sex, center, duration of follow-up, aspirin treatment group, multivitamin use and plasma B2, B6, B12 and folate as appropriate
¥
p-value for interaction